Search

Author/Creator Kebenko, Maxim

1. A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. (9th June 2020)

Authors:
Fiedler, Walter; Chromik, Joerg; Amberg, Stefanie; Kebenko, Maxim; Thol, Felicitas; Schlipfenbacher, Vera; Christine Wilke, Anne; Modemann, Franziska; Janning, Melanie; Serve, Hubert; Ganser, Arnold; Bokemeyer, Carsten; Theile, Susann; Deppermann, Ute; Kranich, Anne L.; Heuser, Michael
Journal:
British journal of haematology
Issue:
Volume 190:Number 3(2020)
Page Start:
e169
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17‐10 CIARA trial). (30th October 2018)

Authors:
Krauter, Jürgen; Fiedler, Walter; Schlenk, Richard F.; Paschka, Peter; Thol, Felicitas; Lübbert, Michael; Wattad, Mohammed; Verbeek, Mareike; Könecke, Christian; Neuhaus, Barbara; Papkalla, Armin; Kebenko, Maxim; Janning, Melanie; Döhner, Konstanze; Gaidzik, Verena I.; Becker, Heiko; Greil, Chris...
Journal:
British journal of haematology
Issue:
Volume 183:Number 2(2018)
Page Start:
235
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. (3rd August 2018)

Authors:
Kebenko, Maxim; Goebeler, Marie-Elisabeth; Wolf, Martin; Hasenburg, Annette; Seggewiss-Bernhardt, Ruth; Ritter, Barbara; Rautenberg, Beate; Atanackovic, Djordje; Kratzer, Andrea; Rottman, James B.; Friedrich, Matthias; Vieser, Eva; Elm, Stefanie; Patzak, Ingrid; Wessiepe, Dorothea; Stienen, Sabin...
Journal:
Oncoimmunology
Issue:
Volume 7:Number 8(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. (29th March 2015)

Authors:
Fiedler, Walter; Kayser, Sabine; Kebenko, Maxim; Janning, Melanie; Krauter, Jürgen; Schittenhelm, Marcus; Götze, Katharina; Weber, Daniela; Göhring, Gudrun; Teleanu, Veronica; Thol, Felicitas; Heuser, Michael; Döhner, Konstanze; Ganser, Arnold; Döhner, Hartmut; Schlenk, Richard F.
Journal:
British journal of haematology
Issue:
Volume 169:Number 5(2015:Jun.)
Page Start:
694
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗